Suppr超能文献

接受左旋多巴/卡比多巴维持治疗的老年帕金森病患者步态的决定因素。

Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy.

作者信息

Bowes S G, Clark P K, Leeman A L, O'Neill C J, Weller C, Nicholson P W, Deshmukh A A, Dobbs S M, Dobbs R J

机构信息

Research Group, Northwick Park Hospital, Harrow, Middlesex.

出版信息

Br J Clin Pharmacol. 1990 Jul;30(1):13-24. doi: 10.1111/j.1365-2125.1990.tb03738.x.

Abstract
  1. We have used gait analysis to investigate the efficacy of maintenance therapy with a levodopa/carbidopa combination in patients with idiopathic Parkinsonism, who do not have overt fluctuations in control in relation to administration of medication. 2. Fourteen patients (aged 64 to 88 years) receiving maintenance therapy with levodopa and carbidopa (Sinemet Plus) entered a placebo-controlled, randomised cross-over study of the effect of omission of a morning dose of active treatment on distance/time parameters of gait. Measurements made 2, 4 and 6 h after the morning treatment were standardised by taking the pre-treatment measurement on that day as baseline. 3. The mean increase in stride length (7%) and decrease in double support time (20%) on active treatment were small but statistically significant (P less than 0.0001, in each case), there being no significant placebo effect on either gait parameter (P = 0.69 and 0.08 respectively). Neither active nor placebo treatments had any significant (P greater than 0.45 in each case) effect on the lying, standing or postural fall in mean arterial pressure, measurements being made in the same temporal relation to the treatments as was gait. 4. In a generalised linear model, after allowing for the effect (P less than 0.0001) of intrinsic variability in pre-treatment speed as well as for structure of the study, nature of treatment had an effect on stride length over the whole walk, significant at P = 0.002. 5. Pre-treatment postural fall in mean arterial pressure was nearly as significant (P = 0.003) as the nature of treatment in the context of such a model: the greater the fall, the greater the increment in stride length seen following active or placebo treatment. This was probably explained by an acquired tolerance to the fall as the day progressed. 6. The major determinant (P less than 0.0001) of the change in double support time over the whole walk, after allowing for the structure of the study, appeared to be the post treatment mean arterial standing blood pressure. The lower the pressure, the shorter the double support time, and hence, the greater the tendency to a hurried gait. 7. Nature of treatment, when added into the models described in summary points 5 and 6, had no significant effect (P greater than 0.25, in each case).(ABSTRACT TRUNCATED AT 400 WORDS)
摘要
  1. 我们运用步态分析来研究左旋多巴/卡比多巴联合维持治疗对特发性帕金森病患者的疗效,这些患者在药物服用方面不存在明显的控制波动。2. 14名接受左旋多巴和卡比多巴(息宁控释片)维持治疗的患者(年龄64至88岁)进入了一项安慰剂对照、随机交叉研究,该研究旨在探究早上漏服一次活性治疗药物对步态距离/时间参数的影响。在早上治疗后2小时、4小时和6小时所进行的测量,通过将当天治疗前的测量值作为基线进行标准化。3. 活性治疗时步幅长度的平均增加(7%)以及双支撑时间的减少(20%)幅度较小,但具有统计学意义(P均小于0.0001),两种步态参数均未出现显著的安慰剂效应(P分别为0.69和0.08)。活性治疗和安慰剂治疗对平均动脉压的卧位、站立位或姿势性下降均无显著影响(P均大于0.45),血压测量与步态测量在与治疗相同的时间关系下进行。4. 在一个广义线性模型中,在考虑了治疗前速度的内在变异性影响(P小于0.0001)以及研究结构后,治疗性质对整个步行过程中的步幅长度有影响,P = 0.002时具有统计学意义。5. 在这样一个模型中,治疗前平均动脉压的姿势性下降几乎与治疗性质同样显著(P = 0.003):下降幅度越大,活性治疗或安慰剂治疗后步幅长度的增加就越大。这可能是由于随着一天的进展对这种下降产生了后天耐受性。6. 在考虑了研究结构后,整个步行过程中双支撑时间变化的主要决定因素(P小于0.0001)似乎是治疗后平均动脉站立血压。血压越低,双支撑时间越短,因此,匆忙步态的倾向就越大。7. 当将治疗性质加入到总结要点5和6中所描述的模型时,均无显著影响(P均大于

相似文献

引用本文的文献

7
Pharmacological treatment in Parkinson's disease: Effects on gait.帕金森病的药物治疗:对步态的影响。
Parkinsonism Relat Disord. 2016 Oct;31:3-13. doi: 10.1016/j.parkreldis.2016.07.006. Epub 2016 Jul 17.

本文引用的文献

1
Parkinsonism in the elderly.
Curr Med Res Opin. 1982;7(Suppl 1):14-22.
3
Assessment of extrapyramidal disorders.锥体外系疾病的评估。
Br J Clin Pharmacol. 1981 Feb;11(2):129-51. doi: 10.1111/j.1365-2125.1981.tb01118.x.
4
Cardiovascular reflexes in Parkinsonism.帕金森病中的心血管反射
Clin Sci. 1971 Jul;41(1):63-7. doi: 10.1042/cs0410063.
5
Autonomic deficits in Parkinson's syndrome.帕金森综合征中的自主神经功能障碍。
Arch Neurol. 1971 Jan;24(1):50-7. doi: 10.1001/archneur.1971.00480310078007.
6
Treatment of Parkinson's disease with levodopa and Ro 4-4602.左旋多巴和Ro 4-4602治疗帕金森病
Clin Pharmacol Ther. 1971 Mar-Apr;12(2):353-9. doi: 10.1002/cpt1971122part2353.
9
Orthostatic hypotension in Parkinson's disease.帕金森病中的体位性低血压
Lancet. 1972 Jan 22;1(7743):174-6. doi: 10.1016/s0140-6736(72)90571-5.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验